Novel botulinum neurotoxin-A tibial nerve perineural injection to alleviate overactive bladder symptoms in male rats

References

• Andersson KE. 2017. On the site and mechanism of action of β3-adrenoceptor agonists in the bladder. Int Neurourol J. 21(1):6.
   PubMed Web of Science ®Google Scholar
• Antoniadis G, Scheglmann K. 2008. Posterior tarsal tunnel syndrome: diagnosis and treatment. Dtsch Ärztebl Int. 105(45):776.
   PubMedGoogle Scholar
• Baarini O, Tan BJ, Edwards SR. 2021. Efficacy of a single botulinum toxin A injection for distal tarsal tunnel syndrome: a protocol for a randomized, double-blinded trial. Contemp Clin Trials Commun. 21:100725.
   PubMed Web of Science ®Google Scholar
• Berthelot L-P, Peyronnet B, Cornu J-N, Aublé A, Brassart E, Bigot P, et al. 2019. Do failure of posterior tibial nerve stimulation precludes to use sacral neuromodulation in patient with overactive bladder? Int Neurourol J. 23(4):287.
   PubMed Web of Science ®Google Scholar
• Birder LA, De Groat WC. 2007. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol. 4(1):46–54.
   PubMedGoogle Scholar
• Breuer B, Sperber K, Wallenstein S, Kiprovski K, Calapa A, Snow B, et al. 2006. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med. 7(1):16–24.
   PubMed Web of Science ®Google Scholar
• Castro-Diaz D, Cardozo L, Chapple C, Espuña M, Kelleher C, Kirby M, et al. 2014. Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences? Int J Clin Pract. 68(3):356–362.
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Fowler CJ, Apostolidis A, De Groat WC, Smith CP, Somogyi GT, et al. 2008. Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol. 5(6):319–328.
   PubMedGoogle Scholar
• Chang CJ, Huang S-T, Hsu K, Lin A, Stoller ML, Lue TF. 1998. Electroacupuncture decreases c-fos expression in the spinal cord induced by noxious stimulation of the rat bladder. J Urol. 160(6 Part 1):2274–2279.
   PubMed Web of Science ®Google Scholar
• Chen J-L, Kuo H-C. 2020. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 61(Suppl. 1):S33–S42.
   PubMedGoogle Scholar
• Chien C-T, Yu H-J, Lin T-B, Lai M-K, Hsu S-M. 2003. Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS. Am J Physiol Renal Physiol. 284(4):F840–F851.
   PubMed Web of Science ®Google Scholar
• Chughtai B, Levin R, De E. 2008. Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. Clin Interv Aging. 3(3):503.
   PubMed Web of Science ®Google Scholar
• Cong H, Liao L, Wang Y, Zhao L, Wang Z, Fu G, et al. 2019. Effects of acute sacral neuromodulation at different pulse widths on bladder overactivity in pigs. Int Neurourol J. 23(2):109.
   PubMed Web of Science ®Google Scholar
• D'ancona CAL, Ferreira RS, Rassi MC. 2012. Botulinum toxin in neurogenic detrusor overactivity. Int Neurourol J. 16(3):139.
   PubMed Web of Science ®Google Scholar
• de Wall LL, Heesakkers JP. 2017. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol. 9:145.
   PubMed Web of Science ®Google Scholar
• Eapen RS, Radomski SB. 2016. Review of the epidemiology of overactive bladder. Res Rep Urol. 8:71.
   PubMed Web of Science ®Google Scholar
• Egeo G, Fofi L, Barbanti P. 2020. Botulinum neurotoxin for the treatment of neuropathic pain. Front Neurol. 11:716.
   PubMed Web of Science ®Google Scholar
• Girtner F, Fritsche H-M, Zeman F, Huber T, Haider M, Pickl C, et al. 2021. Randomized crossover-controlled evaluation of simultaneous bilateral transcutaneous electrostimulation of the posterior tibial nerve during urodynamic studies in patients with lower urinary tract symptoms. Int Neurourol J. 25(4):337–346.
   PubMed Web of Science ®Google Scholar
• Hernández-Hernández D, Padilla-Fernández B, Castro Romera M, Hess Medler S, Castro-Díaz D. 2021. Long-term outcomes of sacral nerve stimulation in pelvic floor dysfunctions. Int Neurourol J. 25(4):319–326.
   PubMed Web of Science ®Google Scholar
• Isner-Horobeti M-E, Muff G, Masat J, Daussin J-L, Dufour SP, Lecocq J. 2015. Botulinum toxin as a treatment for functional popliteal artery entrapment syndrome. Med Sci Sports Exerc. 47(6):1124–1127.
   PubMed Web of Science ®Google Scholar
• Jhang J-F, Kuo H-C. 2018. Novel applications of onabotulinumtoxin A in lower urinary tract dysfunction. Toxins. 10(7):260.
   PubMed Web of Science ®Google Scholar
• Jiang Y-H, Chen S-F, Kuo H-C. 2020. Frontiers in the clinical applications of botulinum toxin A as treatment for neurogenic lower urinary tract dysfunction. Int Neurourol J. 24(4):301.
   PubMed Web of Science ®Google Scholar
• Juan-García FJ, Formigo-Couceiro J, Barrio-Alonso M, Ouviña-Arribas R. 2016. Effectiveness of botulinum toxin type A in carpal tunnel syndrome. J Musculoskelet Res. 19(02):1650006.
   Google Scholar
• Jung G, Im Y-J, Jang G, Suh JK, Park K. 2021. Endoscopic botulinum toxin injection for refractory enuresis based on urodynamic assessment. Int Neurourol J. 25(3):236–243.
   PubMed Web of Science ®Google Scholar
• Kaya CS, Yılmaz EO, Akdeniz-Doğan ZD, Yucesoy CA. 2020. Long-term effects with potential clinical importance of botulinum toxin type-A on mechanics of muscles exposed. Front Bioeng Biotechnol. 8:738.
   PubMed Web of Science ®Google Scholar
• Keck C. 1962. The tarsal-tunnel syndrome. J Bone Jt Surg. 44(1):180–182.
   Web of Science ®Google Scholar
• Kiel J, Kaiser K. 2018. Tarsal tunnel syndrome.
   Google Scholar
• Kim JW, Kim SJ, Park JM, Na YG, Kim KH. 2020. Past, present, and future in the study of neural control of the lower urinary tract. Int Neurourol J. 24(3):191.
   PubMed Web of Science ®Google Scholar
• Kim MK, Shin YS, Lee JH, Cho WJ, Kim DK. 2022. The prevalence of lower urinary tract symptoms and overactive bladder in South Korea: a cross-sectional, population-based study. Int Neurourol J. 26(1):31–36.
   PubMed Web of Science ®Google Scholar
• Law H-Z, Amirlak B, Cheng J, Sammer DM. 2010. An association between carpal tunnel syndrome and migraine headaches – national health interview survey. Plast Reconstr Surg Glob Open. 3:3.
   Google Scholar
• Li X, Wan X, Wang Z, Liang Y, Jia Z, Zhang X, et al. 2021. Frequency-dependent effects on bladder reflex by saphenous nerve stimulation and a possible action mechanism of tibial nerve stimulation in cats. Int Neurourol J. 25(2):128–136.
   PubMed Web of Science ®Google Scholar
• Liao C-H, Kuo H-C. 2015. Practical aspects of botulinum toxin-A treatment in patients with overactive bladder syndrome. Int Neurourol J. 19(4):213.
   PubMed Web of Science ®Google Scholar
• Lightner DJ, Gomelsky A, Souter L, Vasavada SP. 2019. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 202(3):558–563.
   PubMed Web of Science ®Google Scholar
• Lin L, Olson ME, Eubanks LM, Janda KD. 2019. Strategies to counteract botulinum neurotoxin A: nature’s deadliest biomolecule. Acc Chem Res. 52(8):2322–2331.
   PubMed Web of Science ®Google Scholar
• Liu Z-Y, Chen Z-B, Chen J-H. 2018. A novel chronic nerve compression model in the rat. Neural Regen Res. 13(8):1477.
   PubMed Web of Science ®Google Scholar
• Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. 2019. Mechanisms of botulinum toxin type A action on pain. Toxins. 11(8):459.
   PubMed Web of Science ®Google Scholar
• Matak I, Tékus V, Lacković Z, Helyes Z. 2017. Involvement of substance P in the antinociceptive effect of botulinum toxin type A: evidence from knockout mice. Neuroscience. 358:137–145.
   PubMed Web of Science ®Google Scholar
• McSweeney SC, Cichero M. 2015. Tarsal tunnel syndrome – a narrative literature review. Foot. 25(4):244–250.
   PubMedGoogle Scholar
• Mechaly A, Diamant E, Alcalay R, Ben-David A, Dor E, Torgeman A, et al. 2021. Isolation and characterization of a highly specific monoclonal antibody targeting the botulinum neurotoxin type E exposed SNAP-25 neoepitope. bioRxiv.
   Google Scholar
• Mechaly A, Diamant E, Alcalay R, Ben David A, Dor E, Torgeman A, et al. 2022. Highly specific monoclonal antibody targeting the botulinum neurotoxin type E exposed SNAP-25 neoepitope. Antibodies. 11(1):21.
   Web of Science ®Google Scholar
• Nugent M, Yusef YR, Meng J, Wang J, Dolly JO. 2018. A SNAP-25 cleaving chimera of botulinum neurotoxin/A and/E prevents TNFα-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons. Neuropharmacology. 138:257–266.
   PubMed Web of Science ®Google Scholar
• Park J, Park HJ. 2017. Botulinum toxin for the treatment of neuropathic pain. Toxins. 9(9):260.
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. 2010. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 183(4):1438–1443.
   PubMed Web of Science ®Google Scholar
• Salari M, Sharma S, Jog MS. 2018. Botulinum toxin induced atrophy: an uncharted territory. Toxins. 10(8):313.
   PubMed Web of Science ®Google Scholar
• Son HS, Oh CY, Choo M-S, Kim HG, Kim JC, Lee K-S, et al. 2022. Efficacy and aafety of DA-8010, a novel M3 antagonist, in patients with overactive bladder: a randomized, double-blind phase 2 study. Int Neurourol J. 26(2):119–128.
   PubMed Web of Science ®Google Scholar
• Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. 2012. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 13(5):327–334.
   PubMed Web of Science ®Google Scholar
• Steers WD. 2002. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 4(Suppl. 4):S7.
   PubMedGoogle Scholar
• Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R, et al. 2003. Prevalence and burden of overactive bladder in the United States. World J Urol. 20(6):327–336.
   PubMed Web of Science ®Google Scholar
• Tsai C-P, Liu C-Y, Lin K-P, Wang K-C. 2006. Efficacy of botulinum toxin type A in the relief of carpal tunnel syndrome. Clin Drug Investig. 26(9):511–515.
   PubMed Web of Science ®Google Scholar
• Waseem Z, Boulias C, Gordon A, Ismail F, Sheean G, Furlan AD. 2011. Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst Rev. Issue 1. Art. No.:CD008257.
   Google Scholar
• Welch MJ, Purkiss JR, Foster KA. 2000. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 38(2):245–258.
   PubMed Web of Science ®Google Scholar
• Woo DH, Hur Y-N, Jang MW, Justin Lee C, Park M. 2020. Inhibitors of synaptic vesicle exocytosis reduce surface expression of postsynaptic glutamate receptors. Anim Cells Syst. 24(6):341–348.
   PubMed Web of Science ®Google Scholar
• Wu JW, Xing YR, Wen YB, Li TF, Xie JF, De Feng Q, et al. 2016. Prevalence of spina bifida occulta and its relationship with overactive bladder in middle-aged and elderly Chinese people. Int Neurourol J. 20(2):151.
   PubMed Web of Science ®Google Scholar
• Zeng J, Zeng S, Jiang C, Lindström S. 2020. Prolonged inhibitory effect of repeated period tibial nerve stimulation on the micturition reflex in the rat. bioRxiv.
   Google Scholar